These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 1684156)
1. In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes. Lynch DH; Namen AE; Miller RE Eur J Immunol; 1991 Dec; 21(12):2977-85. PubMed ID: 1684156 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic elimination of syngeneic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice. Lynch DH; Miller RE Eur J Immunol; 1991 Jun; 21(6):1403-10. PubMed ID: 1904359 [TBL] [Abstract][Full Text] [Related]
3. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. Shu SY; Chou T; Rosenberg SA J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816 [TBL] [Abstract][Full Text] [Related]
4. Production of interleukin 2 and interleukin 4 by immune CD4-CD8+ and their role in the generation of antigen-specific cytotoxic T cells. Horvat B; Loukides JA; Anandan L; Brewer E; Flood PM Eur J Immunol; 1991 Aug; 21(8):1863-71. PubMed ID: 1907920 [TBL] [Abstract][Full Text] [Related]
5. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. Mulé JJ; Yang J; Shu S; Rosenberg SA J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106 [TBL] [Abstract][Full Text] [Related]
6. Induction of murine lymphokine-activated killer cells by recombinant IL-7. Lynch DH; Miller RE J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262 [TBL] [Abstract][Full Text] [Related]
7. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype. Lynch DH; Daynes RA; Hodes RJ J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117 [TBL] [Abstract][Full Text] [Related]
8. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. Yoshizawa H; Chang AE; Shu S J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072 [TBL] [Abstract][Full Text] [Related]
9. IL-7 supports the generation of cytotoxic T lymphocytes from thymocytes. Multiple lymphokines required for proliferation and cytotoxicity. Bertagnolli M; Herrmann S J Immunol; 1990 Sep; 145(6):1706-12. PubMed ID: 2118152 [TBL] [Abstract][Full Text] [Related]
10. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. Kagamu H; Shu S J Immunol; 1998 Apr; 160(7):3444-52. PubMed ID: 9531305 [TBL] [Abstract][Full Text] [Related]
11. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells. Yoshizawa H; Chang AE; Shu SY Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321 [TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T lymphocyte precursor cells specific for the major histocompatibility complex class I-like antigen, Qa-2, require CD4+ T cells to become primed in vivo and to differentiate into effector cells in vitro. Muraoka S Eur J Immunol; 1991 Sep; 21(9):2095-103. PubMed ID: 1679712 [TBL] [Abstract][Full Text] [Related]
13. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency. Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574 [TBL] [Abstract][Full Text] [Related]
14. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma. Sakai K; Chang AE; Shu SY Cancer Res; 1990 Jul; 50(14):4371-6. PubMed ID: 2114215 [TBL] [Abstract][Full Text] [Related]
15. IL-10: a novel cytotoxic T cell differentiation factor. Chen WF; Zlotnik A J Immunol; 1991 Jul; 147(2):528-34. PubMed ID: 1906502 [TBL] [Abstract][Full Text] [Related]
16. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone. Cerundolo V; Lahaye T; Horvath C; Zanovello P; Collavo D; Engers HD Eur J Immunol; 1987 Feb; 17(2):173-8. PubMed ID: 3030766 [TBL] [Abstract][Full Text] [Related]
17. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor. Matsumura T; Krinock RA; Chang AE; Shu S Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926 [TBL] [Abstract][Full Text] [Related]
18. Effect of rabbit anti-asialo GM1 treatment in vivo or with anti-asialo GM1 plus complement in vitro on cytotoxic T cell activities. Stitz L; Baenziger J; Pircher H; Hengartner H; Zinkernagel RM J Immunol; 1986 Jun; 136(12):4674-80. PubMed ID: 3486908 [TBL] [Abstract][Full Text] [Related]
19. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma. Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908 [TBL] [Abstract][Full Text] [Related]
20. Studies on the minimum requirements for in vitro "cure" of tumor cells by cytotoxic T lymphocytes. Miki S; Ksander B; Streilein JW Reg Immunol; 1992; 4(6):352-62. PubMed ID: 1297406 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]